Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Autologous MUC1-activated T-cells |
Synonyms | |
Therapy Description |
Autologous MUC1-activated T-cells are T-cells that have been activated with MUC1 peptides, which may stimulate an antitumor immune response (PMID: 34611479). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Autologous MUC1-activated T-cells | Autologous MUC1-activated T-lymphocytes | Autologous MUC1-activated T-cells are T-cells that have been activated with MUC1 peptides, which may stimulate an antitumor immune response (PMID: 34611479). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05411497 | Phase I | Autologous MUC1-activated T-cells Cyclophosphamide | Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT06483048 | Phase I | Autologous MUC1-activated T-cells Cyclophosphamide Bendamustine | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | Recruiting | USA | 0 |